INDEX

Absorbed dose, 229
Absorbed dose meter, 230
Accidents. See Medical response in peacetime nuclear accidents
ACH. See Acetylcholine
Acetylcholine (ACH), 126
Acquired immune deficiency syndrome (AIDS), 182
Active vaccination
in the immunosuppressed, 79
Acute radiation syndrome (ARS), 13, 15-33
pathophysiological subsyndromes of, 16-21
prodromal stage of (see Prodromal stage of ARS)
Adenine, 197
Addresses, 275
AET. See Aminoethylisothiouronium
AFRRI (Armed Forces Radiobiology Research Institute)
address, 275
Age
effect of, on cancer risk after radiation exposure, 184-185
AIDS. See Acquired immune deficiency syndrome
Alginates, 62
Alkalosis, 49
Alopecia, 177
Alpha particles, 8, 21-23, 229-230, 246
Alpha radiation, 229-230
Aminoethylisothiouronium (AET), 263
Aminothiols, 250-255, 257
derivative of, 250-254
mercaptopropionylglycine (MPG), 251, 255
Amphetamines
and locomotor hyperactivity after irradiation, 133
Amylase, 86-87, 92
Anesthesia and pain control, 48
Ankylosing spondylitis, 188
Anorexia, 27
and gamma radiation, 86
Antibiotics, 27-28, 75-78
broad-spectrum, 81
potential synergy between, and radioprotectants, 265-266
Antidiarrheals. See Antiemetics and antidiarrheals
Antiemetics and antidiarrheals, 48-49, 133
Antihistamine
in radioprotection, and behavior, 132
Antioncogenes, 183
Antioxidants
   naturally occurring, as radioprotection, 250, 255-256
Arrhythmias, 42
ARS. See Acute radiation syndrome
Aspermia, 90, 175
   duration, 175
   latency, 175
   recovery, 175
   see also Somatic radiation effects, sterility, in males
Ataxia telangiectasia, 182, 202
   and its effect on skin radiosensitivity, 177
Atmospheric testing, 173-174
   see also Fallout
Atom, 2-3
Attentional focusing, 160

Bacillus Calmette-Guérin (BCG), 259
Background radiation, 172-173
   from consumer products, 174
   from extraterrestrial radiation
      cosmic radiation, 172-173
      solar-flare radiation, 172-173
   from fallout, 173-174
   from medical procedures, 172
   sources
      potassium-40, 173
      sodium-24, 173
      thorium-232, 173, 174
   see also Radon gas
Barium sulfate, 62
BCG. See Bacillus Calmette-Guérin
Becquerel (Bq), 228
Behavioral changes in irradiated animals
   cognitive performance, 108-109
   learning and memory, 107-108
   motor performance, 109
   naturalistic behaviors
      consumption, 111
      curiosity and investigatory behaviors, 110-111
      locomotion, 110
      social behavior, 111
      taste aversions, 111-112
Beta burn, 177
   in atomic-bomb survivors and Marshall Islanders, 177
   threshold radiation dose of various isotopes, 177-178
   see also Somatic radiation effects, on skin and hair
Beta-carotene, 256
Beta-mercaptopethylamine (MEA), 263
Beta particles, 8, 21-23, 229
Beta radiation, 229
    and lymphocytes, 94
    shielding, 229
    and skin injury, 42
Biofilms, 69-70
Biological dosimetry, 86
    see also Blood serum dosimeters, Chromosomal dosimeters, Dosimeters,
    Hematological dosimeters, and Urinary Dosimeters
Biological mediators
    as altered by radiation, 181
Blast, 2
    LD$_{50}$ of, 6
Blast effects, 4-7
    blast wave, 6-7
    blast wind, 6-7
    protection from, 6-7
Blast injuries, 6
    triage of, 46
Blast wave. See Blast effects
Blast wind. See Blast effects
Blocking and diluting agents, 63
Blood component therapy, 49-50
Blood serum dosimeters, 91-92
    diamine oxidase (DAO), 91-92
    animal response, 91
    with combined injuries, 92
    plasma haptoglobin, 92
    plasma hemoglobin, 92
    serum alkaline phosphatase in rats, 92
    serum amylase, 86, 90, 91
    lack of animal model, 91
    and parotid gland exposure, 91
    serum lactate dehydrogenase, 92
    see also Dosimeters
Bloom's syndrome, 182, 202
Bone-marrow transplantation, 50, 75, 86
    behavioral benefits of, 134
    in Chernobyl, USSR, 11, 259
    military practicality of, 134
    versus autologous and/or syngeneic transplant, 29
    see also Radioprotection
Bq. See Becquerel
Breast cancer, 184, 193-195
latency, 193
and radiation induction, 193
   age dependence, 193
Bremsstrahlung, 5, 9, 117
Burn injuries
   flame burns, 7
   flash burns, 7
   full-thickness, 79
   LD$_{50}$ for, 7
   partial-thickness, 79
   prophylactic management of, 79
   protection from, 7
   triage of, 46
see also Eye injuries, Thermal effects

Cancer, 179-197
   bone, 184
   Burkitt's lymphoma, 183, 184
   colon, 182
   incidence of, 182
   intestinal, 184
   laryngeal, 184
   liver, 184
   lung, 172, 182, 184, 194-197
   myeloid leukemia, chronic, 184
   myeloma, 182
   prostate, 182
   reproductive system, 197
      and gender differences in incidence, 182
   stomach, 182, 184
   T-cell leukemia, 184
see also Breast cancer, Digestive system cancers, Genetic syndromes
   associated with cancer susceptibility, Leukemia, Ovarian cancer,
   Respiratory system cancers, Thyroid cancer
Cancer formation stages
   initiation, 180-181
   latency, 180-181
   promotion, 180-182
see also Models for predicting cancer incidence
Cancer induction, 179-184
   and radiation dose, 184
Cancer promoters, 180-182
   environmental agents, 182
   hormones, 181, 192
Carbon-14. See Fallout and Radioisotopes
Carboxypenicilllin, 78
Carcinogenic agents and groups, 181
   as listed by the National Toxicology Program, 181
Case shock, 5, 9
CAT. See Computed axial tomography
Catalase, 255
Cataracts. See Somatic radiation effects, cataract formation
Ceftazidime, 75
Central venous catheters
   for fluid and electrolyte therapy, 49
Cesium-137. See Fallout and Radioisotopes
Chelating agents, 63
   deferoxamine (DFOA), 63
   diethylenetriaminepentaacetic acid (DTPA), 50, 62, 63
      dose, 50, 63
      as investigational new drug (IND), 63
      and renal damage, 63
   dimercaprol, 63
   ethylenediaminetetraacetic acid (EDTA), 50, 63
      contraindications, 50
      dose, 50
   penicillamine, 63
"Chemical casualty" in sign language, 46-47
Chernobyl, USSR, nuclear plant accident at, 10-11, 27, 46,
   71, 90, 128, 238-239, 259
Chromosomal aberrations, 184, 188
   with acute lymphocytic leukemia, 188
   with chronic myelogenous leukemia, 188
   radiation induced, 197, 200
   and X chromosome, 199
   see also Antioncogenes, Genetic radiation effects,
      Oncogenes, Proto-oncogenes
Chromosomal dosimeters
   cultured peripheral blood lymphocyte technique, 94-95
      problems with, 94-95
      and radiation dose and type, 94
   micronuclei technique, 94, 96
      and control values, 96
      and bone-marrow transplant cells, 96
   premature condensed chromosome (PCC) technique, 94, 95-96
      and standardized kit, 96
      and time required, 96
   see also Dosimeters
Ci. See Curie
Cisplatin
   and WR-2721, 250
Clavulanic acid, 75
Clearance time, 56
Clinical-support therapy
  effect of, on LD50 dose-effect curve, 27-28
Cobalt-60
  primate survival after irradiation, 259
Cockayne's syndrome, 202
Codon, 197
Combined injuries, 14
  animal studies, 25-26, 27, 112
  and dosimetry problems, 97-98
  in Japan, 27
  see also Management of combined-injury casualties and
    Triage of patients with combined injuries
Computed axial tomography (CAT), 122
Conditioned taste aversion (CTA), 111
Cord factor. See Trehalose dimycolate
Corynebacterium parvum, 259
Cosmic radiation. See Extraterrestrial radiation
Creatine, 92
Critical period
  for teratogenic radiation effects, 206
CTA. See Conditioned taste aversion
Cultured peripheral blood lymphocyte technique, 94-95
Curie (Ci), 228
Cyclophosphamide, 181
  and WR-2721, 250
Cysteine, 263
Cytokines, 259, 261-263, 267
  erythropoietin, 261
  granulocyte-macrophage colony-stimulating factor (GM-CSF), 50, 261-262
  interferons, 261
  interleukin-1 through interleukin-6, 261-263
  tumor necrosis factor (TNF), 252, 261-263
  see also Recombinant leukocyte stimulatory factors
Cytosine, 197
Daniels, J., 2
DAO. See Blood serum dosimeters, diamine oxidase
Day After, The, 156
Dazopride (5-HT3-receptor Mocker)
  as an antiemetic, 133
Debridement, 48, 57, 62, 69, 70, 79, 241
Deferoxamine (DFOA), 63
Delayed fallout, 9
Denial, 157
Deoxyribonucleic acid (DNA), 12
bases of, 197
damage to, and cell death, 246, 248
see also Genetic syndromes associated with susceptibility to cancer
Desquamating lesions, wet and dry, 42, 178-179
Determinants of psychological dysfunction in conventional warfare
  battle duration, 154
  for the British (World War II), 154
  in European theater (World War II), 154
  battle intensity, 154
  in Sicilian campaign (World War II), 154
  communication, 155
  consequences of incapacitation, 155
  for Germans at Stalingrad (World War II), 155
cultural expectations, 155
  in Korean War, 155
  in Vietnam War, 155
  in World War II (in Arakan campaign, Burma), 155
group characteristics, 154
  among Israelis in Yom Kippur War, 154
  physical strain, 154-155
Deuterium, 4
Dexamethasone
  in managing emesis, 133
DFOA. See Deferoxamine
Diabetes
  and its effect on skin radiosensitivity, 177
Diamine oxidase (DAO), 91-92
  see also Radiation exposure, biological indicators
Diethylenetriaminepentaacetic acid (DTPA), 50, 62, 63
Digestive system cancers, 194
  and Thorotrast induction, 194
Diluting agents. See Blocking and diluting agents
Disintegrations per minute (dpm), 228
District of Columbia, 157
dl-alpha-tocopherol. See Vitamin E
DNA (Defense Nuclear Agency)
  address, 275
DNA. See Deoxyribonucleic acid
Dose reduction factor (DRF), 250
Dose-response curve, 23
  modification of, 24
Dosimeters, 86-98, 164, 231
  fluorometric immunoassay, 97
  of MN antigens, 97
  individual military, wristwatch-sized, 164
  problems with, 97-98
radiophotoluminescent (RPL) dosimeters, 231
thermoluminescent dosimeters (TLD), 231
whole-body radionuclide determination, 97
  iodine-131, 97
  sodium-24, 97

see also Blood serum dosimeters, Chromosomal dosimeters, Hematological dosimeters, Radiation detection and measurement, and Urinary dosimeters

Dosimetry
  in Chernobyl, USSR, 10

Double pulse
  of thermal output, 5, 7

Doubling dose
  of radiation, 202

Down's syndrome, 200, 202
dpm. See Disintegrations per minute

DRF. See Dose reduction factor

DTPA. See Diethylenetriaminepentaacetic acid

E = mc^2, defined, 3

Early fallout, 9

Early performance decrement (EPD), 113, 116, 117, 126, 128

Early transient incapacitation (ETI), 13, 42, 113
  ameliorated by WR-1607, 133, 253
  and shielding, 133-134

Edison, Thomas, 179

EDTA. See Ethylenediaminetetraacetic acid

EEG. See Radiogenic neuropathology, in electroencephalograph (EEG) recordings

Eicosanoids, 250, 256

Electrolytes, 49

Electrophysiology
  radiation-induced changes, 124-125

Emesis, 111-112
  induced by WR-1607, 133
  induced by WR-2721, 250

Emetics, 62

Endorphins, 127

Endotoxin, 70, 259-260

Enhanced radiation weapon. See Neutron bomb

Environmental carcinogens. See Cancer promoters, environmental agents

Enzymatic detoxification, 249-250, 255-256

Enzymes, 256

EPD. See Early performance decrement

Epilation, 86, 177,179

EPSP. See Excitatory postsynaptic potential

Erythema, 41, 86, 178-179
see also Radiation injury, cutaneous phenomena; Skin damage;
and Skin erythema dose (SED), defined
Erythrocytes, 50, 90
Erythropoietin, 261
Estrogens, 133
Ethiofos. See WR-2721
Ethylendiaminetetraacetic acid (EDTA), 50, 63
ETI. See Early transient incapacitation
EUCOM. See U.S. European Command (EUCOM)
Chernobyl Task Force
Excitatory postsynaptic potential (EPSP), 125
Exothermic process, 2
Exposure geometry, 24-25, 26, 28-29
Exposure meter, 230
Extraterrestrial radiation, 172-173
  cosmic radiation, 172-173
  and radioprotection, 134
  solar-flare radiation, 172-173
Eye injuries
  at Chernobyl, USSR, 46
  and combatants, 46
  corneal edema, 175
  flash blindness, 7
  foveal damage, 46
  lacrimal gland atrophy, 175
  occupational radiation exposure limit, 175
  protection from, 7
  retinal burn, 7
  triage of, 46
see also Neurophysiology of performance decrements
  and Somatic radiation effects, cataract formation
Fallout, 4, 9-10, 173-174
  from carbon-14, 173-174
  from cesium-137, 173
  from strontium-90, 173
see also Radiation hazards in patient treatment and Radioisotopes
Fallout decay
  estimating, 235-236
  predicting hazards, 10
Fallout shelters
  dozer trench, 236
  dug-in mobile hospital tents, 236
  operation of, 236
  vehicle-earth shelter, 236
Fanconi's anemia, 182, 202
Federal Emergency Management Agency (FEMA), 239
   address, 275
FEMA. See Federal Emergency Management Agency
Fibronectin, 72-73
Fission, defined, 4
Fission fragments, 4
   see also Radioisotopes
Fission weapons
   fuel, 4
      plutonium-239, 4
      uranium-233, 4
      uranium-235, 4
   gun-assembled device, 4
   implosion device, 4
Fluorometric immunoassay, 97
Follicle stimulating hormone (FSH), 176
Forward therapy, 164
   Israeli experiences with, 164
Free-radical scavenging, 249-251, 255-256, 257
Free radicals, 172, 246-248, 257
FSH. See Follicle stimulating hormone
Fusion, 4
   see also Radioisotopes
Fusion weapons, 4
   see also Radioisotopes
Gamma radiation, 59, 172, 229
   acute doses of, 86
   and blood cell effects, 90
   and lymphocyte count, 87, 89, 94
   median doses of, for ARS symptoms, 86
   shielding, 229, 236
   and skin injury, 41-42
Gamma rays, 4, 8-9, 13, 21, 246
Gardner's syndrome, 182
Gastrointestinal subsyndrome, 13-14, 18-19
   and nutritional support, 50-51
Geiger-Mueller (GM) counters, 59, 230
Genetic approaches to radioprotection, 248, 250, 256, 257
Genetic radiation effects, 197-205
   estimating risks, 202-205
   gene mutations, 197-200
      factors affecting mutation, 200-202
Genetic syndromes associated with susceptibility to cancer, 182
   ataxia telangiectasia, 182, 202
   Bloom's syndrome, 182, 202
Fanconi's anemia, 182, 202
Gardner's syndrome, 182
Li-Fraumeni's syndrome, 182, 184
xeroderma pigmentosum, 182, 202
Genetically significant dose (GSD), 202
Glasgow coma scale, 38
Glucan, 252, 258, 260-261, 264, 266
Glutathione, 263
Glutathione peroxidase, 255
Glycine, 92
GM. See Geiger-Mueller (GM) counters
GM-CSF. See Granulocyte-macrophage colony-stimulating factor
Goggles, lead-lanthanum-zirconium-titanium, 7
Goiânia, Brazil, radiation accident at, 29, 41, 56, 62
Gonadotropin, 176
Gram-negative organisms, 68, 70-72, 74, 77-79
Gram-positive organisms, 68, 70, 71, 77, 78
Granulocyte-macrophage colony-stimulating factor (GM-CSF), 50, 260, 262
Granulocytes, 50, 90
Granulocytopenia, 72
Gray (Gy), defined, 172, 229
"Ground zero," 157
GSD. See Genetically significant dose
Guanine, 197
Guidelines for medical advisors, 240
Gun-assembled device, 4
Gy. See Gray (Gy), defined
Half-life, defined, 228
Haloperidol, 126
Haptoglobin, 92
Healthy worker effect, 191
Hematological dosimeters, 42-43, 87-90
in Chernobyl, USSR, 90
erthrocytes, 90
granulocytes, 90
latency, 90
lymphocytes, 87-88, 89
platelets, 90
reticulocytes, 90
see also Blood serum dosimeters, Dosimeters
Hematopoietic depression, 27, 90
Hematopoietic precursor cells, 90
see also Stem cells
Hematopoietic subsyndrome, 13, 16-18, 90
and burn injury, 46
infection in, 71
Hematopoietic stem cells, 263
    regeneration of, 257-263
    shielding of, 28
Hemoglobin, 92
Hemorrhage, 90
Hemorrhagic coagulopathies, 42
High-LET radiation, 21, 246
    and radioprotection, 248
    and teratogenic effects, 208
Histamine, 19, 41, 92, 126, 127, 135, 172
HIV. See Human immunodeficiency virus
Human immunodeficiency virus (HIV), 182
Huntington's chorea, 199
Hybridoma technology, 79
Hydrocephaly, 210
Hydroxyproline, 92
Hyperthermia, 42
Hypocalcemia, induced by WR-2721, 250
Hypoglycemia, 42
Hypokalemia, 42, 49
Hyponatremia, 49
Hypotension, 42
Hypoxemia, 42
Hypoxia
    induction of, as radioprotection, 249, 250
ICRP. See International Commission on Radiological Protection
IL-1. See Interleukin-1
IL-3. See Interleukin-3
Immunoglobulin, 48, 73, 79
Immunomodulators, 259-261
Immunosuppression, 72-73
    and malnutrition, 50
    in Chernobyl victims, 27
    by radiation in cancer latency, 181
Impaired inflammatory response, 72-73
Implosion device, 4
IND (investigational new drug), 63
Infection, 67-81
    contributors to, 79
    control of, 48
        with glucan, 260-261
        as limiting factor in treatment, 27
    in Chernobyl, 71
in hematopoietic subsyndrome, 71
see also Infection management
Infection management, 75-80
  antibiotics, 75-78
  supportive therapy, 76-79
  surgery, 79-80
see also Antibiotics
Infections associated with radiation injury, 71-72
  predisposing factors, 72-75
see also Opportunistic infections
Infectious agents. See Pathogens
Inhibitory postsynaptic potential (IPSP), 125
Initial nuclear radiation, 4, 5
  effects of, 7-10
Initial Response Force (IRF), 239
Integrating meter, 230
Interferons, 261
Interleukin-1 (IL-1), 252, 260, 261-263, 264
Interleukin-3 (IL-3), 262
Internal decontamination, 55-64
  clearing the gastrointestinal tract, 62
    alginates, 62
    aluminum antacids, 62
    barium sulfate, 62
    emetics, 62
    ion exchangers, 62
    phytates, 62
    purgatives and laxatives, 62
    stomach lavage, 62
  preventing or reversing radiobiological interaction, 63
    blocking and diluting agents, 63
    chelating agents, 63
    lung lavage, 63
    mobilizing agents, 63
see also Chelating agents
Internal radionuclide contamination, 55-64
  clearance time, 56
  ingestion, 56-57
  inhalation, 56-57
    model for evaluating hazards of, 56
  percutaneous absorption, 56
  wound contamination, 56-57
International Atomic Energy Agency (IAEA), 95
  address, 275
International Commission on Radiological Protection (ICRP), 56, 175, 202
Index

Ion exchangers, 62
Ionization, 229
Ionization chambers, 59, 230
    pocket dosimeter, 230
Ionizing radiation, 246
IPSP. See Inhibitory postsynaptic potential
IRF. See Initial Response Force
Irradiation
    synergy, with open wound, 79

Kiloton (kt), 4
    see also Megaton
kt. See Kiloton.

Lactate dehydrogenase, 86, 87
Laxatives and purgatives, 62
LD\textsubscript{50} (lethal dose, or fatal injury, for 50 percent of cases), 6, 23
    and dependence on dose rate, 31
    establishing, of radiation for humans, 29-30
        in air, 29
        to bone marrow, 29, 33
        data sources for, 29-30
    and exposure geometry, 24-25, 26
    in Hiroshima, 32
        for humans, 31-33
        for low-LET radiation, 31-33
    and radiation quality, 24-25
    and trauma, 25-27
Lead-lanthanum-zirconium-titanium goggles, 7
LET. See Linear energy transfer
Lethality curve, 23-24
Leukemia, 182, 184, 188-191
Leukotriene C\textsubscript{4} (LTC\textsubscript{4}), 252, 256
Li-Fraumeni's syndrome, 182, 184
Linear energy transfer (LET), 21
Lipopolysaccharide (LPS) cell-wall component, 70
    see also Endotoxin
Los Alamos, NM, radiation accident at, (Mr. K.), 127-128
Low-LET radiation, 21, 177, 246
    and radioprotection, 248
LPS. See Lipopolysaccharide (LPS) cell-wall component
LTC\textsubscript{4}. See Leukotriene C
Lung cancer, 172, 182, 184, 194-197
Lung lavage, 63
Luteinizing hormone, 176
Lymphocytes, 87-90, 261
count as a biological dosimeter, 87-90
nomogram, 42-43,

Lymphoma
Burkitt's, 183, 184

Macrophages, 72, 261, 262
Mafenide acetate (sulfamylon), 79
Management of combined-injury casualties, 46-52
anesthesia and pain control, 48
antiemetics and antiarrheals, 48-49
atropine, 49
diphenoxylate HCl, 49
codeine, 49
hydrocortisone enemas, 49
serotonin (5-HT3) blocking agents, 48-49
blood component therapy, 49-50
anemia and, 49
and autologous platelets, 49
and erythrocytes, 50
and granulocytes, 50
chelation therapy, 50
fluids and electrolytes, 49
infection control, 48
nutritional support, 50-51
surgery, 47-48

see also Chelating agents

Management of contaminated patients
hospital management, 57-59
initial care, resuscitation, and admission, 241
on-site management, 57
in combined nuclear-chemical war, 57
operating-room care, 242
patient decontamination, 60-63, 234-235
rescue and evacuation in a nuclear accident, 240
sampling radioactivity, 57
supply checklist, 58
treatment decisions, 60
uptake and clearance, 56-57

see also Internal radionuclide contamination

Management of mass casualties, 232-233
combined injuries, 232
command radiation guidance, 232-233
logistical support, 232
psychological stress, 232
public health, 232
Manhattan Project, 2
MAO. See Monoamine oxidase
Marshall Islanders, effects of radiation on, 177-178, 179, 192, 193
Mass defect, 3
Maturation-depletion, 90
MEA. See Beta-mercaptoethylamine
Medical advisor guidelines, 240
Medical Radiobiology Advisory Team (MRAT), 240
Medical response in peacetime nuclear accidents
information demand, 237
see also
Chernobyl, USSR, nuclear power plant accident at;
Goiania, Brazil, radiation accident at;
Los Alamos, NM, radiation accident at (Mr. K.);
Oak Ridge, TN, radiation accident at;
Palomares, Spain, nuclear accident at;
Providence, RI, radiation accident at (Mr. P.);
Three Mile Island, nuclear power plant, accident at;
Thule Air Force Base, Greenland, accident at;
and Vinca, Yugoslavia, radiation accident at
Megaton (MT), 4
see also Kiloton
Menopause
induced by radiation, 193
Menstrual cycle
effect of radiation on, 177
Mercaptopropionylglycine (MPG), 251, 255
Metoclopramide (5-HT3-receptor blocker)
as antiemetic, 133
MFP. See Mixed fission products
Microbes
population changes, 73-75
Microcephaly, 207, 209
Micronuclei technique, 94, 96
Military operations in fallout, 235-236
Military performance
radiation-induced changes, 129-132
Military response to nuclear accident or incident
Initial Response Force (IRF), 239
On-Scene Commander (OSC), 239-240
Service Response Force (SRF), 239
Mixed-fission products (MFP), 60
Mobilizing agents, 63
Models for predicting cancer incidence, 184-187
and leukemia incidence among Nagasaki survivors, 184-187
linear, 184-187
linear-quadratic, 184, 187
pure quadratic with cell killing, 184, 187
quadratic, 184, 187
Monoamine oxidase (MAO), 126
Monoclonal antibodies, 79
Morphine, 127
Mortality
  radiation-induced, 90
  reduced by radioprotectants, 133
MPG. See Mercaptopropionylglycine
MRAT. See Medical Radiobiology Advisory Team
n-decylationethanethiosulfuric acid (WR-1607), 133
  see also WRAIR sulfur compounds
Naloxone, 127
NATO Standardization Agreement (STANAG 2083), 233
Nausea, 42
  gamma radiation dose for, 86
  induced by WR-2721, 250
Necrosis, 41, 42, 48, 62, 120, 121, 123, 175, 178, 179, 214, 261
Neoplasm, 180
  see also Cancer
Neurochemistry
  radiation-induced changes, 125-126
Neurological changes induced by radiation, 105-135
Neuropathological changes. See Radiogenic neuropathology
Neurophysiology of performance decrements
  audition and vestibular function, 120-121
  olfactory function, 121
  gustatory function, 121
  vision, 119-120
Neuropsychiatric casualties
  prediction of, 163-164
Neurotransmitters, 126
Neurovascular subsyndrome, 13, 14, 19-21
Neutron bomb, 4
Neutron particles, 3, 4, 8-9, 13, 229, 230, 246
Neutron radiation, 229, 230
  and biological effects, 211
  shielding, 230
Nitrogen mustard, 181
Nondisjunction, 200
NTIS (National Technical Information Service)
  address, 275
nts. See Nuclear transformations per second
"Nuclear casualty" in sign language, 46-47
Nuclear energy, 2-5
  kinetic energy, 2
  potential energy, 2
Nuclear transformations per second (nts), 228
Nuclear weapons
  nuclear and physical processes, 2-5
Nuclear Weapons Accident Checklists, 243
Nutritional support
  of combined-injury casualties, 50-51
Nystatin, 78

Oak Ridge, TN, radiation accident at, 30
OCLC (Online Computer Library Center)
  address, 275
On-Scene Commander (OSC), 239-240
Oncogenes, 183-184
Opiates
  in radioprotection, and behavior, 132
Opportunistic infections, 68-71
  pathogens, 79
OSC. See On-Scene Commander
Ovarian cancer, 197
Ovaries
  radiosensitivity, 176-177
  see also Somatic radiation effects, sterility, in females

PAF See Platelet-activating factor
Palomares, Spain, nuclear accident at, 327
Pathogens
  Bacteroides, 68
  Clostridium, 68, 69
  Enterobacter, 68
  Escherichia, 68, 73
  Klebsiella, 68, 73
  Pseudomonas, 68, 69
  Staphylococcus, 68, 70, 73
  Streptococcus, 68
Pathophysiological subsyndrome stages
  latent, 16
  manifest illness, 16
  prodromal, 16
  recovery, 16
Patient management
  principles of, 81
PCC. See Premature condensed chromosome (PCC) technique
Peacetime radiation accidents. See Medical response in peacetime nuclear
accidents
Pefloxacin, 266
Performance decrements, 113-118
  mitigating, through radioprotection, 132-134, 264
  and radiation dose, 115-116
  and radiation dose rate, 116, 118
  and radiation quality, 117
  role of CNS in, 133-134
  and task complexity, 113-115
Philadelphia chromosome, 184, 188
  see also Chromosomal aberrations
Phosphorothioates, 253, 254
Photon, 229
Physical dosimeters. See Dosimeters
Physiological mediators, 247, 249
Phytates, 62
Plasma
  of ions and electrons, 5, 6
Platelet-activating factor (PAF), 252, 256
Plateletpheresis, 49
Platelets, 49, 90
Plutonium. See Fission weapons, fuel, plutonium-239
Pneumonitis, 42
Polydactyly, 206
Post-traumatic stress disorder (PTSD), 161-162
Postirradiation infections. See Infections
Premature condensed chromosome (PCC) technique, 94, 95-96
Prodromal stage of ARS, 16, 17, 86
  dose-dependent latent stage of, 86
  duration and severity, 86, 88
  onset and latency, 86, 88
  symptoms, 86, 88
Proportional counters, 59, 230
Prostaglandin inhibitors
  to minimize skin damage, 178
Prostaglandins, 92, 172, 256
  16, 16-dimethyl prostaglandin E\textsubscript{2} (DiPGE\textsubscript{2}), 252, 256, 264
Proto-oncogenes, 183, 184
Protons, 3
Providence, RI, radiation accident at (Mr. P.), 128
Prussian blue, 62
Psychic numbing, 157, 159
Psychological casualties
  care of, 164-165
  and morale, 165
  and uncertainty about personal injury, 164
differences in nuclear warfare versus conventional warfare, 155-156
  • description by Hiroshima survivor, 155-156
  • after Three Mile Island accident, 156
  • in U.S. Strategic Bombing Survey, 156
prediction of, and military performance, 163-164
prevention of, 165-166
and self-preservation, 165
and social cohesion, 166
training recommendations, 165-166
  • in World War II, 154
  • in Yom Kippur War, 154, 166

see also Determinants of psychological dysfunction in conventional warfare

Psychological changes (acute)
  • fear and terror, 160
    • from U.S. Strategic Bombing Survey, 160
  • in learning and memory, 161
    • absence of conditioned response in animals, 161
    • in Hiroshima survivors, 161
    • retrograde amnesia in animals, 161
    • from Soviet literature, 161
  • in motivation, 158-160
    • in animals, to receive brain stimulation, 158
    • in animals, of curiosity and attention, 158-159
    • in Hiroshima and Nagasaki, 159-160
  • in social relations, 160-161
    • attention to leaders, 160
    • maintenance of social structure, 160-161

Psychological effects of nuclear warfare. See Psychological changes (acute) and Psychological reactions (chronic)

Psychological factors in nuclear warfare, 153-166

Psychological reactions (chronic)
  • anxiety and phobias, 162
    • in Hiroshima, 162
    • and rumors, 162
  • latency of, 161
  • neuroses, 161
    • in Japan, 161
  • post-traumatic stress disorder (PTSD), 161-162
    • after natural disasters, 161-162
    • depression in, 162
    • diagnostic criteria, 162
    • principal features, 162
  • psychoses, 161
    • temporary, among new combat units, 161
  • psychosomatic symptoms, 163
survivor guilt, 162-163
PTSD. See Post-traumatic stress disorder
Purgatives and laxatives, 62

QBC 11 assay methodology, 43
Quinolones, 75

R. See Roentgens (R), defined
R-meter, 230
Rad, defined, 172, 229
Radiation, 2, 228
"Radiation casualty" in sign language, 46
Radiation counter, 230
Radiation detection and measurement, 59-60, 230-231
Geiger-Mueller (GM) counters, 59, 230
film badges, 60
ionization chambers, 59, 230
proportional counters, 59, 230
radiophotoluminescent (RPL) dosimeters, 231
scintillation counters, 59, 230-231
surface monitoring, 59
thermoluminescent dosimeters (TLD), 60, 231
see also Dosimeters
Radiation dose, 115-116, 230
and cancer induction, 184
doubling, 202
and performance decrement, 115-116
Radiation dose rate, 116, 184
and performance decrement, 116, 118
Radiation Emergency Assistance Center/Training Site (REAC/TS), Oak Ridge, TN, 63, 240
address, 275
Radiation exposure
accidents, 30-31
biological indicators, 86, 87
case histories, 127-128
data sources on, 189
regulatory guides, 212-213
required to damage organs, 175-187
units of measure, 172 (see also Gray, Rad, Rem, Roentgens, Sievert)
Radiation Exposure Status (RES) category system, 233
Radiation hazards in patient treatment, 234
beta-contact, 234
internal, 234
whole-body gamma radiation, 234
see also Management of contaminated patients and Medical advisor
guidelines
Radiation injury, 12-13
- cardiovascular, respiratory, metabolic, and neurological phenomena, 42
  - arrhythmias, 42
  - early transient incapacitation (ETI), 42
  - hemorrhagic coagulopathies, 42
  - hyperthermia, 42
  - hypoglycemia, 42
  - hypotension, 42
  - pneumonitis, 42
- cutaneous phenomena, 41-42
  - erythema, 41
  - melanotic pigmentation, 41
  - necrosis, 41
  - skin sensations, 41
  - ulceration, 41
- gastrointestinal phenomena, 42
  - in combined chemical-nuclear environments, 42
  - diarrhea, 42
  - nausea and vomiting, 42
- hematological phenomena, 42-43
  - and blood cell morphology, 42-43
  - and lymphocyte nomogram, 42-44
  - symptoms of, 40-41
  see also Beta burn, Skin damage, Somatic radiation effects on skin and hair
Radiation quality, 12, 24-25, 117
- and cancer induction, 184
- and performance decrement, 117
Radioactive material, 228
Radioactivity, 228
Radiogenic neuropathology, 122-124, 157, 158-163
  - of beta-endorphin, 158
  - cerebral ischemia, 123
  - cortex, 122
  - data from Japan, 157
  - demyelination, 121, 123
  - of dopamine metabolism, 158
  - dorsal medulla, 122
  - in electroencephalograph (EEG) recordings, 158
  - glial cells, 123
  - hippocampus, 123
  - hypothalamus, 122
  - morphology, 122
  - necrosis, 121, 123
  - optic chiasm, 122
Radioisotopes, 4, 173-174
and chelation therapy, 50
treatment of contamination by, 60-61
see also Dosimeters, Whole-body radionuclide determination,
and Management of contaminated patients
Radiological Advisory Medical Team (RAMT), 240
address, 275
Radiolysis
products of, 172
water, 250
Radiomimetic agents, 181
cyclophosphamide, 181
nitrogen mustard, 181
Radionuclide contamination. See Internal radionuclide contamination
Radioluminescent (RPL) dosimeters, 231
see also Dosimeters and Radiation detection and measurement
Radioprotection, 245-269
and behavior, 132-134
in space, 134
and supportive therapy, 264-266
see also Antiemetics and antidiarrheals, Radioprotective agents,
Radioprotective strategies, Shielding
Radioprotective agents
aminothiols, 250-255, 257
combination agents, 263-266
cytokines, 259, 261-263
of detoxification, 252, 255
eicosanoids, 250, 256
genetic approaches, 250, 256
naturally occurring antioxidants, 250, 255-256
of regeneration, 252, 257-263
Radioprotective regimen requirements, 266-268
deliverability, 267-268
effectiveness, 266-267
toxicity, 267
Radioprotective strategies
protection, 248-256
free radical scavenging, 249-250
hypoxia, 249
regeneration, 248, 257-263
repair, 248, 257
genetic, 257
hydrogen transfer, 257
Radiotherapy, 29-30
Radon gas, 172
daughter products
polonium-214, 172
polonium-218, 172
radon-220, 172
radon-222, 172
RAMT. See Radiological Advisory Medical Team
Ratemeter, 230
RBE. See Relative biological effectiveness
REAC/TS. See Radiation Emergency Assistance Center/
   Training Site (REAC/TS), Oak Ridge, TN
Reciprocal translocation, 200
Recombinant granulocyte-macrophage colony-stimulating factor, 260
Recombinant leukocyte stimulatory factors, 50
Relative biological effectiveness (RBE), 25
Rem, 172
Rem-meter, 230
RES. See Radiation Exposure Status (RES) category system
RES. See Reticuloendothelial system
Residual radiation, 5, 7-10, 236
   effects of, 7-10
   estimating decay of, 236
Respiratory system cancers, 172, 182, 184, 194-197
Reticulocytes, 90
Reticuloendothelial system (RES), 72
Retrograde amnesia, 107
Ribonucleic acid (RNA), 200
RNA. See Ribonucleic acid
Roentgen, Wilhelm Conrad, 2, 177
Roentgens (R), defined, 172
RPL. See Radiophotoluminescent (RPL) dosimeters

Salting, 9
Scintillation counters, 59, 230-231
SED. See Skin erythema dose
Segmented filamentous microflora (SFM), 74
Selenium
   as radioprotectant, 252, 255, 256, 264
   to reduce toxicity of WR-2721, 256
Serotonin
   as radioprotective agent, 263
Serum amylose, 86, 87, 90, 91
Service Response Force (SRF), 239
SFM. See Segmented filamentous microflora
"Shell shock" syndrome, 164
Shielding, 28-29, 133-134, 235-236, 267
   see also Radioprotection
Sievert (Sv), defined, 172
Sign language
for "chemical casualty," 46-47
for "radiation casualty," 46-47
Silvadene. See Silver sulfadiazine
Silver sulfadiazine (silvadene), 79
Skin damage, 177-179
  beta burn, 178
  cancer, 178-179
  epilation, 179
  erythema, 178-179
    neutron radiation threshold, 178
  fibrosis, 179
  fingernail pigmentation, 179
    in Marshall Islanders, 179
  hyperpigmentation, 179
  hypopigmentation, 179
  necrosis, 178-179
  and radiation dose, 178
  telangiectasia, 179
  transepithelial injury (moist desquamation), 178-179
  ulceration, 178-179
  see also Beta burn, Erythema
Skin decontamination, 48, 60-62
Skin erythema dose (SED), defined, 177
  exposure proposed for radiologists, 177
  of X radiation, 177
Somatic cell fusion (hybridoma technology), 79
Somatic radiation effects, 175-187
  cataract formation, 175
    among Nagasaki survivors, 175
    incidence, 175, 176
    latency, 175
    radiation threshold, 175
  on skin and hair, 177-179
    as affected by disease, 177
    alopecia, 177
    from alpha radiation, 177
    dermatitis, 177
    epilation, 177, 179
    see also Beta burn, Skin damage
  sterility, 175-177
    in females, 176-177
    in males, 175-176
    see also Cancer induction
Spina bifida, 210
SRF. See Service Response Force
STANAG. See NATO Standardization Agreement (STANAG 2083)
Stem cells
  bone marrow, 25, 90
  depletion of, 248
  hematopoietic, 25, 28, 90, 263
    mitotic delay or destruction of, 90
  regeneration, capability of, 28
  stromal, 90
  survival of, increased, 263
Stem formation, 9
Sterility, 175-177
Steroids
  and managing emesis, 133
Stomach lavage, 62
Strong force, 3
Strontium-90. See Fallout and Radioisotopes
Stunting, 208
Sulfamylon. See Mafenide acetate
Sulfhydryls, 253, 254
Superoxide dismutase, 252, 255, 256
Surgery, 47-48, 79
  and antibiotics, 79
  timing of, after irradiation, 79
Sv. See Sievert
Symptoms of irradiation, 88

T-cell leukemia, 184
T-cells
  activation of, by interleukin-1, 261
  in AIDS, 182
    T-4 lymphocytes, 182
Taurine, 92
TDM. See Trehalose dimycolate
Teenagers
  survey of, on likelihood of nuclear war, 156
Telangiectasia, 179
Television dramatization. See Day After, The
Teratogenic radiation effects, 205-211
  embryonic developmental stages, 205
    fetal, 205, 208
    major organogenesis, 205, 206-208
    preimplantation, 205, 206
  humans irradiated in utero, 209-211
    and fetal mortality, 209
    and greater cancer incidence, 211
    in Hiroshima, 207
Testes
radiosensitivity, 175

see also Somatic radiation effects, sterility, in males

Testosterone, 176

Therapeutic index, defined, 250

Thermal effects, 7

production of, 4-5

Thermal force, 2

Thermoluminescent dosimeters (TLD), 60, 231

see also Dosimeters and Radiation detection and measurement

Thiola. See Mercaptopropionylglycine

Thiosulfonates, 253, 254

Thorotrast, 189

Three Mile Island, PA, nuclear power plant accident at, 156

Thule Air Force Base, Greenland, accident at, 238

Thymine, 197

Thyroid cancer, 182, 184, 185, 191-193

and ethnic groups, 192

prevalence in women, 191-193

and thyroid irradiation, 193

TLD. See Thermoluminescent dosimeters

TNF. See Tumor-necrosis factor

Trauma, influence of,

on LD$_{50}$, 25-27

Trehalose dimycolate (TDM), 252, 260-261, 265

Triage, 11, 37-46

of blast injury, 46

of burn injury, 46

of eye injury, 46

military, 40

of patients with combined injuries, 43-46

and radiation dose, 40, 45

in peacetime, 39-40

priority categories, 38-39

delayed treatment, 38

expectant, 38

immediate treatment, 38

minimal treatment, 38

Trinity device, 4

Tritium, 4

Tumor-necrosis factor (TNF), 252, 261-263, 264

Turner's syndrome, 206

Ulceration, 41, 178-179

Uranium. See Fission weapons, fuel, uranium-233 and uranium-235

Urinary dosimeters, 87, 92

amylase, 87, 92
creatinine, 87, 92
glycine, 92
hindrances to development, 92
histamine, 87, 92
hydroxyproline, 92
prostaglandins, 87, 92
taurine, 87, 92
see also Dosimeters
U.S. European Command (EUCOM) Chernobyl Task Force, 238-239
address, 275

Vaccination. See Active vaccination
Vinca, Yugoslavia, radiation accident at, 30-31
Vitamin A, 251, 256
Vitamin E, 251, 256

Walter Reed Army Institute of Research (WRAIR), 250, 254
address, 275
Weapon yield, 5
Whole-body radionuclide determination, 97
Wound closure, 79
and immunosuppression, 79
and systemic sepsis, 79
WR-2721 (ethiofos), 133, 250-254, 264
WRAIR. See Walter Reed Army Institute of Research
WRAIR sulfur compounds, 133, 250-254

X radiation, 172
and cancer induction, 179
and cancer treatment, 179
exposure to, 177
and lymphocytes, 94
see also Radiotherapy
X rays, 2, 246
plasma as source of, 5
Xeroderma pigmentosum, 182, 202

Yield. See Weapon yield

Zacopride (5-HT3-receptor blocker)
as antiemetic, 133
Zinc protoporphyrin (ZPP), 86, 87, 97
ZPP. See Zinc protoporphyrin
Zymosan, 259-260

Return to Table of Contents